Please assess the completion status of the following clinical trial:

Trial Title: SNIFF 120: Study of Nasal Insulin to Fight Forgetfulness (120 Days)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age 55 or greater~* Good physical health~* Memory impairment with a diagnosis of mild cognitive impairment (MCI) or Alzheimer's disease (AD)~* Participants on stable doses of Memantine (Namenda) or cholinesterase inhibitors will be eligible~Exclusion Criteria:~* Chronic sinus problems/allergies with chronic use of nasal decongestants or antihistamines~* Significant neurologic disease that might affect cognition (other than AD), such as stroke, Parkinson's disease, multiple sclerosis, severe head injury with loss of consciousness for more than 30 minutes or with permanent neurologic symptoms~* Significant medical illness or organ failure, such as uncontrolled hypertension or cardiovascular disease, chronic obstructive pulmonary disease, liver disease, or kidney disease~* Preexisting diabetes or current or previous use of hypoglycemic agents or insulin; participants will be excluded if they have a fasting blood sugar greater than 165 on baseline OGTT~* Clinically significant elevations in liver function tests, cholesterol, or triglycerides~* Major psychiatric disorders (e.g., untreated major depression and schizophrenia)~* Chronic use of the following types of medications: anti-psychotic, anxiolytic, and opiates

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): saline
- 2 (Type: EXPERIMENTAL): 10 Units
- 3 (Type: EXPERIMENTAL): 20 Units

Based on this trial design, predict the completion outcome and termination type (if applicable).